Clinuvel Pharmaceuticals stock forecast
Clinuvel Pharmaceuticals (UR9) Stock Forecast & Price Target
UR9 Analyst Ratings
UR9 Stock 12 Month Forecast
Average Price Target
CHF9.32▲(124.14% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Iain Wilkie | Morgans | CHF5.70→CHF3.99 | hold | -4.04%Downside | Downgraded | 10/21/26 | ||
| Sarah Mann | MA Financial Group | CHF8.23 | buy | 97.82%Upside | Reiterated | 08/30/26 | ||
| David Stanton | Jefferies | CHF23.26→CHF22.41 | buy | 438.76%Upside | Reiterated | 08/30/26 | ||
| Thomas Wakim | Bell Potter | CHF6.56 | hold | 57.65%Upside | Downgraded | 08/27/26 | ||
| Madeleine Williams | Canaccord Genuity | CHF5.43 | hold | 30.51%Upside | Downgraded | 08/27/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Iain WilkieMorgans | HoldDowngradedCHF5.70→CHF3.99 | 10/21/26 | -4.04%Downside | ||
| Sarah MannMA Financial Group | BuyReiteratedCHF8.23 | 08/30/26 | 97.82%Upside | ||
| David StantonJefferies | BuyReiteratedCHF23.26→CHF22.41 | 08/30/26 | 438.76%Upside | ||
| Thomas WakimBell Potter | HoldDowngradedCHF6.56 | 08/27/26 | 57.65%Upside | ||
| Madeleine WilliamsCanaccord Genuity | HoldDowngradedCHF5.43 | 08/27/26 | 30.51%Upside |
Best Analysts Covering Clinuvel Pharmaceuticals
Copying David Stanton's trades and holding each position for 3 Months would result in 27.27% of your transactions generating a profit, with an average return of -9.22% per trade.
Copying David Stanton's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -18.05% per trade.
Copying David Stanton's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -26.23% per trade.
UR9 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 0 |
| Buy | 0 | 1 | 1 | 1 | 0 |
| Hold | 0 | 3 | 3 | 4 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 2 | 6 | 6 | 6 | 1 |
In the current month, UR9 has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. UR9 average Analyst price target in the past 3 months is 9.32.
UR9 Financial Forecast
UR9 Earnings Forecast
Next quarter’s earnings estimate for UR9 is CHF 0.14 with a range of CHF 0.11 to CHF 0.20. The previous quarter’s EPS was CHF 0.27. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
UR9 Sales Forecast
Next quarter’s sales forecast for UR9 is CHF 20.66M with a range of CHF 20.24M to CHF 21.04M. The previous quarter’s sales results were CHF 32.55M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
